Table 1.

Patient characteristics.

Patient	Sex	Age	cTNM	Pathology	Location primary tumor
1	Female	55	T2N2M0	AC	RUL; PTV0 and PTV3 not near PRV
2	Male	61	T2N2M0	SCC	LLL; PTV0 and PTV3 overlap aorta PRV, near spinal cord and bronchial tree
3	Male	49	T2N2M0	AC	ML; PTV0 and PTV3 overlap heart PRV
4	Male	60	T3N2M0	SCC	RUL; PTV0 overlaps bronchial tree PRV
5	Female	49	T3N2M0	AC	LUL; PTV0 and PTV3 overlap heart, aorta and bronchial tree PRV
6	Female	52	T4N3M0	NSCLC NOS	LH; PTV0 and PTV3 overlap heart, aorta and bronchial tree PRV
7	Male	70	T3N2M0	AC	RUL; PTV0 and PTV3 overlap heart PRV
8	Male	66	T4N0M0	SCC	LUL; PTV0 and PTV3 overlap brachial plexus and great vessels PRVs. Near spinal cord and esophagus
9	Male	61	T1N2M0	AC	ML; PTV0 and PTV3 not near PRV
10	Female	49	T2N2M0	NSCLC NOS	LUL; PTV0 and PTV3 overlap heart PRV

Abbreviations: AC: adenocarcinoma; cTNM: clinical tumor node metastasis staging system 7th edition; LLL: left lower lobe; LUL: left upper lobe; LH: left hilum; ML: middle lobe; NOS: not otherwise specified; PTV₀: boost planning target volume determined on pre-treatment ¹⁸F-FDG-PET/CT; PTV₃: boost planning target volume determined on the early response monitoring ¹⁸F-FDG-PET/CT; PRV: planning organ at risk volume; RUL: right upper lobe; SCC: squamous cell carcinoma